The current standard for assessing tumor response in clinical trials - RECIST, performed by human readers - can be challenged by investigator bias, subjectivity in lesion selection and measurement variability. To address this, Quibim has partnered with Friends of Cancer Research on its artificial intelligence-based measurement of response evaluation criteria in solid tumors (ai.RECIST) project. The ai.RECIST project evaluates AI-based tumor measurement tools to: ✔️ Provide consistent and accurate tumor measurements ✔️ Align with expert RECIST readouts ✔️ Reduce variability and streamline trials Check Quibim's AI-supported RECIST tool, embedded in QP-Insights: https://bit.ly/3ELhH3p #aiRECIST #AIinResearch
The PROVIDENCE study, sponsored by Johnson & Johnson, S.A. in collaboration with Quibim, leverages artificial intelligence to predict metastatic relapse in patients with intermediate- to high-risk localized #ProstateCancer. 📊 Clinical data and diagnostic imaging are analyzed using the QP-Insights® platform to support non-invasive, real-time risk stratification. Interim results (n=127) demonstrate promising predictive performance for biochemical recurrence (AUC: 0.79), with surgery, PSA levels, and ISUP grade identified as key clinical predictors. Final results, currently in progress, will incorporate quantitative imaging biomarkers to further advance personalized treatment strategies. Read the full study here: https://bit.ly/42qjK4X #AIinHealthcare #MedicalImaging #Oncology #PrecisionMedicine
Our CEO and Co-Founder Dr. Ángel Alberich-Bayarri will join the stage at the European Conference on Interventional Oncology (ECIO) in Rotterdam to discuss: 𝘌𝘵𝘩𝘪𝘤𝘢𝘭, 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘊𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘷𝘦 𝘜𝘴𝘦𝘴 𝘰𝘧 𝘈𝘐 𝘪𝘯 𝘐𝘯𝘵𝘦𝘳𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘢𝘭 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺. 🗓️ April 13, 2025 🕥 10:30–12:00 CET 📍 Auditorium 2, Rotterdam Ahoy Convention Centre - Rotterdam, The Netherlands 🎤 Moderators: Fernando Gómez Muñoz & Bernhard Meyer Join us for a critical conversation on how AI can be implemented responsibly to improve patient care. #InterventionalOncology #AIinHealthcare #EthicalAI #ECIO2025
This morning, we participated in the first edition of 𝘔𝘪𝘤𝘳𝘰𝘴𝘰𝘧𝘵 𝘏𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦 𝘋𝘢𝘺 in Madrid, an initiative organized by SEDISA (The Spanish Society of Healthcare Managers) in collaboration with Microsoft. The event aims to modernize the Spanish healthcare system through AI-powered technological solutions. Representing Quibim, our Chief Operations Officer Alberto Valiente Montoro, and Director of Business Development - EMEA, LATAM & APAC Javier Pizcueta Pastor, participated in the panel on the medical diagnosis and early detection of high-impact diseases. They shared how we apply artificial intelligence to transform the way these conditions are identified and managed. 👏 A big thank you for creating this space for innovation and fostering stronger collaboration between healthcare and technology. #DigitalHealth #ArtificialIntelligence #HealthcareInnovation
📢 Our CEO & Co-Founder Ángel Alberich-Bayarri participated in a Campus Sanofi Unboxing episode to share his vision on how AI is already helping radiologists detect diseases more accurately. Spanish-speaking healthcare professionals are sure to be interested! 👇
Q1 2025 was a significant quarter at Quibim: 💡 Discover the latest tech and research in AI for healthcare 📢 Key publications and clinical perspectives 📊 Performance highlights and company news Stay ahead of the curve, subscribe to our newsletter! 📩 https://bit.ly/4lnusC5 #MedicalImaging #HealthAI #Innovation
With renewed leadership, FDA clearance for QP-Prostate CAD and a $50M Series A, Quibim enters a new era of growth and strategic expansion that will certainly scale and shape the future of precision healthcare. Introducing our new Board of Directors: ▪️ Tom Tynes, Founder of T2 MedTech, LLC (Independent Director) ▪️ Pierre Socha, Partner at Amadeus Capital Partners ▪️ Romain Lavault, General Partner at Partech ▪️ Guillem Masferrer, Partner at Asabys Partners ▪️ Jose Mesa, Partner at COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and Buenavista Equity Partners (formerly GED Capital)’s representative on the Board ▪️ Dr. Ángel Alberich-Bayarri, CEO & Co-Founder of Quibim One of the new members of the Board of Directors is Tom Tynes, who joins as an independent director. Tom brings a wealth of experience, having led the launch, profitable growth, and success of several medical device companies over the past 30 years. https://bit.ly/4i6Qczc
💊 AI is transforming how we develop new treatments, accelerating the path from discovery to #patientcare. By leveraging machine learning, data mining, and predictive modeling, AI is optimizing every stage of drug development—making the process faster, smarter, and more precise. #MachineLearning #MedicalInnovation #AIinHealth
CADt, CADe, CADx – What’s the Difference? AI-based computer-aided triage (CADt), detection (CADe) and diagnosis (CADx) are becoming increasingly important in medical imaging: ⚡ 𝐂𝐀𝐃𝐭 – Identifies potentially urgent cases to prioritize their review, without making a diagnosis. 🩺 𝐂𝐀𝐃𝐞 – Flags suspicious regions on medical images to assist as a second reader. 🔬 𝐂𝐀𝐃𝐱 – Analyzes and characterizes lesions to support diagnostic decisions. So... is CADe/x a game-changer in radiology? We break it all down in our latest blog 👉 https://bit.ly/4hZIuaa #AIinHealthcare #Radiology #MedicalImaging #AIPoweredCAD #PrecisionMedicine
March was a month of major milestones at Quibim! ✅ The FDA cleared QP-Prostate® CAD — great news for U.S. specialists who can now access our AI-powered tool designed to reveal hidden cases of aggressive #ProstateCancer. 💡 We also shared expert insights from Antonio José Conde Moreno MD PhD MSc and Prof. Shonit Punwani, and published new research on neuroblastoma in 𝘍𝘳𝘰𝘯𝘵𝘪𝘦𝘳𝘴 𝘪𝘯 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺. 🚀 Let’s not forget our latest innovations showcased at #ECR25. Catch up on all the highlights in our newsletter 👇 #AIinHealthcare #CancerScreening #Innovation
